KACTUS have developed a dsRNA Quick-Quantification Kit to detect the presence of undesired dsRNA molecules in IVT reactions or dsRNA in viral/non-viral nucleic acid extracts.
KACTUS: MDA5 dsRNA Quick-Quantification Kit

KACTUS have developed a dsRNA Quick-Quantification Kit to detect the presence of undesired dsRNA molecules in IVT reactions or dsRNA in viral/non-viral nucleic acid extracts.
KACTUS has carefully developed a highly sensitive spCas9 detection kit.
KACTUS’ AAV ELISA kits using recombinant monoclonal antibodies are developed using their proprietary immunisation scheme that overcomes the weak AAV immunogenicity.
KACTUS has developed a series of high-activity enzyme for in vitro synthesis of DNA vectors, based on their SAMS™ technology platform.
KACTUS have used their SAMS™ protein production platform to develop high-quality enzymes for in vitro synthesis of mRNA (GMP-Grade & GMP-Ready).
KACTUS has developed a GMP-grade universal nuclease – MaxNuclease™, which degrades all DNA and RNA into 2-5 base oligonucleotides.
At KACTUS, they have developed a highly-active, wild-type Cas9 nuclease based on their SAMS™ technology platform.
AccuBase® is a cytosine base editor that converts a C-G base pair into a T-A base pair in the genome. Designed by Base Therapeutics, manufactured by KACTUS.
KACTUS has developed a series of high-quality CAR-T target protein products, covering a wide range of popular targets such as CD19, BCMA, and MSLN.
At KACTUS, they offer a comprehensive range of high-quality recombinant HLA-G and LILR proteins, to support research and development in immunology and therapeutic applications.